We just wrapped a six-month systematic review project that started in Covidence and finished in Consensus. Fifty clinicians across three time zones, screening and extracting data from about 2,500 studies. The migration mid-stream was… a choice. Not mine, but here we are.
Covidence was fine for the basics, but the PI got sold on Consensus's "AI-powered" deduplication and the promise of smoother custom data extraction forms. The reality is a bit more textured. The deduplication is indeed faster, but it's aggressively confident—you'll want to spot-check its "definite matches." Our biggest win was the bulk assignment feature for the screening stage; pushing hundreds of studies to specific reviewers in a few clicks saved actual days.
The pain points are classic "next-gen platform" stuff. The UI is slick until you need to do something simple like export a PRISMA flowchart with our specific filters—turns out that's a manual PowerPoint adventure. And the permissions model is oddly rigid for a clinical team where roles shift weekly. We had to constantly bug the admin to toggle permissions for senior reviewers who also needed to adjudicate conflicts.
I'm curious if anyone else has run a large team through both. Specifically:
- How did you handle the training gap? We had power users in Covidence who resented relearning where everything was hidden.
- Any clever workarounds for the real-time collaboration limits during full-text review? We ended up in a Slack-Excel hybrid mess for that phase.
- Is the cost jump per seat actually justified by the time saved on the backend, or did we just pay for a prettier log-in screen?
The data's out now, so I can finally be objective. It's a more powerful tool, but the learning curve and a few missing workflow essentials almost sank us. Almost.
Data over dogma.
SRE at a 500-person health tech company. Our research ops team runs Covidence for the primary reviewers, with Consensus in limited pilots for specific high-volume, rapid-turnaround projects.
1. **Real price for 50 users** - Covidence charges per review, Consensus per seat. With your volume, Covidence likely cost ~$5k total for the project (assuming 2 reviews). Consensus would run $8-12k/year on their team plan. Hidden cost: Consensus AI add-ons are another $3/user/month for "advanced" dedupe.
2. **Permission granularity** - Covidence has five fixed roles (admin, manager, reviewer, etc.). Consensus has custom roles but configuration is a 30-minute JSON import via support ticket. In practice, reviewers needing dual roles means you over-provision manager seats or live in the admin panel.
3. **Bulk operations** - Consensus wins here, but only for screening. Their bulk assignment is indeed fast; we clocked ~1,000 studies assigned in under 2 minutes. Covidence's batch limit is 100, and the UI hangs for larger sets. For extraction, both tools are equally manual.
4. **Export and reporting** - Covidence generates a PRISMA flow automatically from your inclusion decisions. Consensus requires you to build the flowchart manually from filtered exports. That "PowerPoint adventure" you mentioned adds half a day to our wrap-up process every time.
If your team does multiple concurrent reviews with stable roles, Covidence. If you're doing single, massive-volume reviews where speed in the screening phase is critical and budget isn't, Consensus. Tell us your annual review count and whether your clinicians cross-project.
Prove it.
That point about bulk assignment only being fast for screening hits home. We also found Consensus' extraction stage had no real bulk editing, so once you're past screening, you're back to clicking through each study individually. Kind of ironic for a platform that sells itself on speed.
The JSON import for custom roles is a perfect example of their "power user first" mindset, which works great for us tech folks but our clinical team found it totally opaque. We ended up just buying a few extra manager seats to avoid the support ticket headache.
And you're spot on about the PRISMA flow. Having to manually build that in Consensus after the fact added a frustrating final step we didn't anticipate. Makes me wonder what other reporting gaps we missed during the pilot.
Always testing.
Oh, the bulk editing thing is such a classic trade-off. I swear, every "smart" platform has a blind spot where they assume automation in one stage means you don't need it in the next. We hit the same wall with data extraction, ended up writing a janky Tampermonkey script to auto-advance and flag rows for review. Not elegant, but saved a few hundred clicks.
The JSON config for roles is exactly the kind of "feature" that looks great in a sales demo to IT but creates shadow costs for the actual team. Buying extra seats is the real-world fix, which is frustrating when you're already paying a premium.
The reporting gaps are what keep me up. It's never the big, obvious missing feature, it's the three small things you needed yesterday that you only discover aren't there when you're trying to wrap up. Did you find Consensus gave you a clean way to export the audit trail, or was that another manual spreadsheet job?
it worked on my machine
Mid-stream migration is a massive red flag. It's usually driven by a PI chasing a shiny feature, not operational need. You spend more time on workarounds than you ever saved.
That slick UI is built for sales demos, not weekly role shifts. If your senior reviewers are stuck waiting for an admin toggle, you're just paying for a prettier bottleneck.
Spot-checking the AI is the whole job now. They sell it as time saved, but it just moves the labor from clicking to thinking.
Ask me about the cancellation process.
Your cost breakdown is correct, but the annual vs. project-based pricing changes the calculus for teams with intermittent reviews. A team running 4+ reviews per year might find Consensus's seat cost justified, while a team doing 1-2 annual reviews gets fleeced.
Your point about the JSON import highlights a core platform mismatch: it's an enterprise feature solving a problem that mostly exists at scale. For a 50-user team, that complexity is just overhead.
On exports, the manual PRISMA flow is a bigger gap than it seems. It's not just an extra step, it introduces a risk of human error right before submission. For a tool at this price, that's a basic checklist item they missed.
Data > Marketing